

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Knudsen et al.

Serial No.: TBA

Group Art Unit: TBA

Filed: June 21, 2001

Examiner: TBA

For: Extendin Derivatives (As Amended)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE SPECIFICATION:

At page 1, please delete the title and insert -- Extendin Derivatives--.

At page 1, replace the paragraph entitled "CROSS-REFERENCE TO RELATED APPLICATIONS" with the following paragraph:

This application is a continuation of USSN 09/312,177 filed 14 May 1999, which is a continuation of PCT/DK99/00086 filed February 24, 1999 and claims priority under 35 U.S.C. 119 of Danish application 0274/98 filed February 27, 1998, and U.S. provisional application 60/084,357 filed May 5, 1998, the contents of which are fully incorporated herein by reference.—

IN THE CLAIMS:

Cancel claims 1-91, and add the following new claims:

92. An exendin derivative having an amino acid sequence that differs from the amino acid sequence of exendin-3 or exendin-4 by the substitution of up to ten amino acid residues with any α -amino acid residue, wherein (a) one or two lipophilic substituents are attached to amino acid residues and (b) one of the lipophilic substituents is attached to an amino acid residue which is not the N-terminal or C-terminal amino acid residue.
93. An exendin derivative of claim 92, having an amino acid sequence that differs from the amino acid sequence of exendin-3 or exendin-4 by the substitution of up to six amino acid residues with any α -amino acid residue.
94. An exendin derivative of claim 93, wherein one lipophilic substituent is present.
95. An exendin derivative of claim 93, wherein two lipophilic substituents are present.
96. An exendin derivative of claim 94, wherein the lipophilic substituent has 4 to 40 carbon atoms.
97. An exendin derivative of claim 96, wherein the lipophilic substituent has 8 to 25 carbon atoms.
98. An exendin derivative of claim 96, wherein the lipophilic substituent is attached by means of a spacer.
99. An exendin derivative of claim 98, wherein the spacer is an unbranched alkane α,ω -dicarboxylic acid group having from 1 to 7 methylene groups.
100. An exendin derivative of claim 99, wherein the spacer is an unbranched alkane α,ω -dicarboxylic acid group having two methylene groups.
101. An exendin derivative of claim 98, wherein the spacer is an amino acid residue except cys, or a dipeptide such as gly-lys.
102. An exendin derivative of claim 96, wherein the lipophilic substituent is a partially or completely hydrogenated cyclopentanophenathrene skeleton.

103. An exendin derivative of claim 96, wherein the lipophilic substituent is a straight-chain or branched alkyl group.

104. An exendin derivative of claim 96, wherein the lipophilic substituent is a straight-chain or branched acyl group.

105. An exendin derivative of claim 104, wherein the acyl group is of the formula $\text{CH}_3(\text{CH}_2)_n\text{CO}-$, wherein n is 4 to 38.

106. An exendin derivative of claim 105, wherein the acyl group is $\text{CH}_3(\text{CH}_2)_6\text{CO}-$, $\text{CH}_3(\text{CH}_2)_8\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{10}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{12}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{14}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{16}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{18}\text{CO}-$, $\text{CH}_3(\text{CH}_2)_{20}\text{CO}-$ or $\text{CH}_3(\text{CH}_2)_{22}\text{CO}-$.

107. An exendin derivative of claim 96, wherein the lipophilic substituent is an acyl group of a straight-chain or branched alkane α,ω -dicarboxylic acid.

108. An exendin derivative of claim 107, wherein the acyl group is of the formula $\text{HOOC}(\text{CH}_2)_m\text{CO}-$, wherein m is from 4 to 38.

109. An exendin derivative of claim 108, wherein the acyl group is $\text{HOOC}(\text{CH}_2)_{14}\text{CO}-$, $\text{HOOC}(\text{CH}_2)_{16}\text{CO}-$, $\text{HOOC}(\text{CH}_2)_{18}\text{CO}-$, $\text{HOOC}(\text{CH}_2)_{20}\text{CO}-$ or $\text{HOOC}(\text{CH}_2)_{22}\text{CO}-$.

110. An exendin derivative of claim 96, wherein the lipophilic substituent is a group of the formula $\text{CH}_3(\text{CH}_2)_p((\text{CH}_2)_q\text{COOH})\text{CHNH-CO}(\text{CH}_2)_2\text{CO}-$, wherein p and q are integers and p+q is an integer of from 8 to 33.

111. An exendin derivative of claim 96, wherein the lipophilic substituent is a group of the formula $\text{CH}_3(\text{CH}_2)_r\text{CO-NHCH}(\text{COOH})(\text{CH}_2)_2\text{CO}-$, wherein r is an integer of from 10 to 24.

112. An exendin derivative of claim 96, wherein the lipophilic substituent is a group of the formula $\text{CH}_3(\text{CH}_2)_s\text{CO-NHCH}((\text{CH}_2)_2\text{COOH})\text{CO}-$, wherein s is an integer of from 8 to 24.

113. An exendin derivative of claim 96, wherein the lipophilic substituent is a group of the formula $-\text{NHCH}(\text{COOH})(\text{CH}_2)_4\text{NH-CO}(\text{CH}_2)_u\text{CH}_3$, wherein u is an integer of from 8 to 18.

114. An exendin derivative of claim 96, wherein the lipophilic substituent is a group of the formula $\text{-NHCH(COOH)(CH}_2\text{)}_4\text{NH-COCH((CH}_2\text{)}_2\text{COOH)NH-CO(CH}_2\text{)}_w\text{CH}_3$, wherein w is an integer of from 10 to 16.

115. An exendin derivative of claim 96, wherein the lipophilic substituent is a group of the formula $\text{-NHCH(COOH)(CH}_2\text{)}_4\text{NH-CO(CH}_2\text{)}_2\text{CH(COOH)NH-CO(CH}_2\text{)}_x\text{CH}_3$, wherein x is an integer of from 10 to 16.

116. An exendin derivative of claim 96, wherein the lipophilic substituent is a group of the formula $\text{-NHCH(COOH)(CH}_2\text{)}_4\text{NH-CO(CH}_2\text{)}_2\text{CH(COOH)NH-CO(CH}_2\text{)}_y\text{CH}_3$, wherein y is zero or an integer of from 1 to 22.

117. An exendin derivative of claim 97, having an amino acid sequence of HEGTFTSDLSKQMEEEAVRLFIEWLKNGGX, wherein X = P or Y, or a fragment or an analogue thereof.

118. An exendin derivative of claim 97, having an amino acid sequence of HX1X2GTFITSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS, wherein X1X2 = SD or GE, or a fragment or an analogue thereof.

119. An exendin derivative of claim 97, having an amino acid sequence of DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS, or a fragment or an analogue thereof.

120. An exendin derivative of claim 92, which is Arg¹⁸, Leu²⁰, Gln³⁴, Lys³³ (N^ε-(γ-aminobutyryl(N^α-hexadecanoyl))) Exendin-4-(7-45)-NH₂.

121. An exendin derivative of claim 92, which is Arg³³, Leu²⁰, Gln³⁴, Lys¹⁸ (N^ε-(γ-aminobutyryl(N^α-hexadecanoyl))) Exendin-4-(7-45)-NH₂.

122. A pharmaceutical composition comprising an exendin derivative of claim 92 and a pharmaceutically acceptable vehicle or carrier.

123. A method of treating insulin dependent or non-insulin dependent diabetes mellitus in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of a exendin derivative of claim 92 and a pharmaceutically acceptable carrier.

REMARKS

Claims 1-91 have been canceled without prejudice or disclaimer. Claim 92-123 have been added and therefore are pending in the present application. Claims 92-123 are supported by original claims 47-91. No new matter is added by this amendment, and entry is respectfully requested.

Respectfully submitted,

Date: 21 June 2001



Valeta A. Gregg, Reg. No. 35,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

0988344-062101
101290-1129860